Start-ups from the DCB ecosystem

Beyond Diagnostics AG: From the INSPIRE Lab at DCB to a pioneering role in medication quality control

The efficacy of insulin is of central importance for people with diabetes. At the same time, insulin, as a protein, is sensitive to heat, light and mechanical stress. As a result, it can lose biological activity without this being visible from the outside. Beyond Diagnostics addresses this previously unresolved challenge with LUMIQ, a rapid test designed to determine the biological activity of insulin directly at the point of care.

The idea behind Beyond Diagnostics, "Bringing Medication Quality to Light", came from Maren Schinz, CEO, who identified the need to reliably assess the quality of insulin and other temperature-sensitive medications directly at the point of care during her role as Innovation Manager at DCB. This question gave rise to the vision of fundamentally transforming medication quality control through innovative rapid tests and digital data interpretation.

The scientific and technological development of LUMIQ is carried out at DCB's INSPIRE Lab. There, the innovation has been gradually advanced into a prototype through close collaboration between research, clinical practice and technology.

Beyond Diagnostics exemplifies how a clinically relevant question and the innovative strength of DCB employees can give rise to an internationally oriented MedTech company with the potential to sustainably change the quality control of biological medications.